Mounjaro
Mounjaro is the brand name of subcutaneous tirzepatide manufactured by Eli Lilly, FDA-approved in 2022 for the treatment of type 2 diabetes. It is administered once weekly at doses of 2.5 mg through 15 mg via prefilled pen injector. Mounjaro is not FDA-approved for weight loss; the same molecule is sold as Zepbound for chronic weight management.
What is Mounjaro?
Mounjaro is the brand name of tirzepatide, a dual GIP/GLP-1 receptor agonist marketed by Eli Lilly for the treatment of type 2 diabetes. It received FDA approval in May 2022 and is delivered as a once-weekly subcutaneous injection from a prefilled pen.
Available doses:
- 2.5 mg / week (initiation only, weeks 1-4)
- 5 mg / week
- 7.5 mg / week
- 10 mg / week
- 12.5 mg / week
- 15 mg / week (maximum)
A separate tirzepatide product, Zepbound, contains the same molecule at the same dose range and is FDA-approved (2023) for chronic weight management. Mounjaro is not FDA-approved for weight loss — its widely reported weight loss effects in non-diabetic users represent off-label prescribing.
How is Mounjaro used?
For type 2 diabetes, Mounjaro is approved as adjunct to diet and exercise to improve glycemic control. Standard titration:
- Weeks 1-4: 2.5 mg/week (acclimation)
- Week 5+: 5 mg/week
- After ≥4 weeks at any dose, may escalate by 2.5 mg increments to a maximum of 15 mg
In the SURPASS-2 head-to-head trial, Mounjaro at 15 mg produced approximately 2.0% greater HbA1c reduction and 5.5 kg greater weight loss than semaglutide 1 mg over 40 weeks. The newer SURMOUNT-5 trial (2024) confirmed weight-loss superiority over semaglutide in non-diabetic adults with obesity.
Why Mounjaro matters for nutrition
Mounjaro produces larger calorie reductions than Ozempic — typically 25-35% — and the resulting nutrition priorities are similar but more pressing:
- Protein adequacy (1.2-1.6 g/kg/day)
- Resistance training to preserve lean mass during rapid weight loss
- Hydration and electrolyte management during GI symptoms
- Slow titration of food volume; small frequent meals often better tolerated
- Multivitamin and B12 supplementation where intake remains very low
Common side effects mirror the GLP-1 class: nausea, vomiting, diarrhea or constipation, abdominal pain, fatigue, reflux. Rare but serious: pancreatitis, gallbladder events. Same thyroid C-cell tumor boxed warning.
This is general educational information, not medical advice. Consult your physician before starting, stopping, or modifying Mounjaro. Dosing, contraindications, side-effect management, and monitoring are decisions that belong to your prescribing clinician.
See tirzepatide, Ozempic, semaglutide, and GLP-1 receptor agonist for related entries.